醫用玻璃概念股走強 正川股份(603976.SH)漲停
格隆匯6月29日丨醫用玻璃概念股走強,正川股份漲停,山東藥玻大漲超7%。6月22日,據外媒稱,新冠病毒疫苗的試驗和生產在急速推進中,然而阻礙大規模量產的或許是玻璃小藥瓶以及原料特種玻璃的短缺。製藥公司和政府正大規模購買容納新冠疫苗的玻璃瓶,僅強生就購買了2.5億支小藥瓶。全球最大醫用玻璃製造商之一肖特公司稱,該公司收到的10億個小藥瓶的訂貨需求是其今年生產能力的兩倍。


Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.